The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Science from our Sisters

Science from our Sisters

June 1, 2007 • By Virginia Hughes

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Glucosamine Hydrochloride Affects Subchondral Bone Growth

In a rabbit model of osteoarthritis (OA), treatment with glucosamine hydrochloride significantly reduced subchondral bone turnover, according to a study in Arthritis & Rheumatism (A&R) (2007;56:1537­-1548).

You Might Also Like
  • Science from our Sisters
  • Science from our Sisters
  • Science from our Sisters
Explore This Issue
June 2007
Also By This Author
  • Catch Some Zs

Glucosamine hydrochloride—a dietary supplement not regulated by the FDA—has long been used to treat OA in humans, with mixed results. In 2001 and 2002, two large clinical trials showed that three years of glucosamine treatment slowed radiographic progression of OA in the knee. Yet in 2006, another randomized, placebo-controlled study in the New England Journal of Medicine found that glucosamine hydrochloride was no better than placebo at controlling knee pain from OA.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Previous studies of the biological workings of glucosamine in animals focused on how the drug affects joint cartilage; this new A&R study was the first to look at how the compound might change the subchondral bone. The authors decided to study subchondral bone changes “because it could explain beneficial outcomes observed in humans in some clinical trials,” says co-author Sheila Laverty, an equine surgeon at the University of Montreal’s veterinary school.

Laverty and colleagues first performed an anterior cruciate ligament transection (ACLT)—a surgical procedure that induces osteoarthritis symptoms—in the knee joints of 16 rabbits. Immediately following the procedure, half the rabbits were given daily doses of glucosamine. After eight weeks, the researchers performed necropsies on all the animals to measure subchondral bone turnover and bone density.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Compared with the control group, glucosamine-treated rabbits had significantly less bone turnover; in most of the bone parameters measured, the glucosamine-treated rabbits were identical to rabbits that had not undergone ACLT. Treatment with glucosamine, Laverty adds, “appeared to offer a protection against the reduction in bone mineral density, subchondral bone plate thickness, and bone connectivity associated with the development of osteoarthritis.”

Still, Laverty cautions against extrapolating these results in the rabbit model to humans. In the model, glucosamine was given from disease onset, while humans are usually studied much later in the disease trajectory. However, she says these findings “could provide some support for the use of glucosamine immediately following joint injury.”

 

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Socioeconomic Factors Affect Access to Rheumatology Care

People with rheumatic diseases, studies have shown, have better treatment outcomes if they see a rheumatology specialist. But are certain segments of the patient population more likely than others to seek and receive specialty care?

To find out, two studies in the May issue of Arthritis Care & Research surveyed almost 1,000 systemic lupus erythematosus (SLE) patients (2007;57:593­-600, 601- 607). The first found that elderly, male, and lower-income patients were the least likely to have seen a specialist in the previous year. The second found that Medicaid patients traveled much further than non-Medicaid patients to see the doctor (whether specialist or not) who treated their condition.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Practice Management, Research Reviews Tagged With: Arthritis & Rheumatology, Arthritis Care & Research, bone, glucosamine, Osteoarthritis, patient care, Research, socioeconomicIssue: June 2007

You Might Also Like:
  • Science from our Sisters
  • Science from our Sisters
  • Science from our Sisters
  • Science from our Sisters

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)